Case report

Severe bradyarrhythmia requiring temporary pacemaker in a COVID-19 patient receiving lopinavir/ritonavir treatment: a case report

Zhenisgul Sh. Tlegenova¹, Bekbolat Zholdin¹, Meirambek S. Kurmangazin¹, Bulat K. Khamidulla², Zhambul E. Zhailybaev²

¹West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
²Aktobe Medical Centre, Aktobe, Kazakhstan

Abstract
A 74-year-old Asian female with a history of hypertension and chronic obstructive pulmonary disease was admitted to hospital for coughing, shortness of breath and fatigue; her nasopharyngeal swab was positive for COVID-19. Lopinavir/ritonavir 800mg/200 mg, daily was started. On the third day of antiviral therapy, the patient complained of dizziness, nausea, she was disoriented, and electrocardiogram showed sinus arrest, junctional escape rhythm 36 beats per min. Patient was successfully treated by temporary pacemaker, normal sinus rhythm was reverted on a 3rd day after stopping the lopinavir/ritonavir treatment. She was discharged home in stable condition. Bradyarrhythmia in form of sinus arrest can develop during treatment with lopinavir/ritonavir. The temporal nature of the observed changes and the ECG finding suggests the use of L/R contributed to the changes. This case highlights off-label prescribing lopinavir/ritonavir outside of a clinical trial setting should be avoided until the data have proven that treatment benefit over placebo.

Key words: COVID-19, bradyarrhythmia, sinus arrest, junctional rhythm, lopinavir, ritonavir, complication, pacemaker

(Heart Vessels Transplant 2020; 4; doi: 10.24969/hvt.2020.198)

Introduction
The coronavirus disease-2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) and now represents the global pandemic (1). COVID-19 is most frequently presents with respiratory symptoms that can progress to pneumonia and in severe cases acute respiratory distress syndrome and shock (2). Currently, there is no available treatment proven to be effective against COVID-19, but multiple agents, including lopinavir and ritonavir (L/R), remdesivir, chloroquine, hydroxychloroquine, ribavirin are used off label (3). The results of studies do not allow us to draw an indisputable conclusion about their effectiveness and safety. It is important to report some of these antiviral agents have cardiac toxicities (4).

We report and discuss the case a 74-year old Asian female who developed severe bradyarrhythmia requiring temporary pacemaker after the L/R treatment.

Case report
A 74-year-old Asian female with a history of hypertension and chronic obstructive pulmonary disease was admitted to hospital with complaints of dyspnea, cough and fatigue. Her polymerase chain reaction (PCR) test for SARS-CoV-2 RNA was found to be positive. Medications prior to admission included perindopril 10 mg and zopiclone 7.5 mg.

Address for Correspondence: Zhenisgul Tlegenova, West Kazakhstan Marat Ospanov Medical University, Email: Tlegenova_G@mail.ru
Received: 25.05.2020 Revised: 05.06.2020 Accepted: 05.06.2020
Copyright © 2020 Heart, Vessels and Transplantation
On examination, her blood pressure was 140/90 mm Hg, heart rate was 84 bpm, respiratory rate of 24 breaths per minute and a room air oxygen saturation of 95%. Her physical examination revealed a scattered bilateral crackles and no peripheral edema. A 12-lead electrocardiogram (ECG) recording at admission showed normal sinus rhythm without clinical abnormalities. She had no personal or family history of arrhythmia.

The patient was treated with L/R 800mg/200 mg daily, according to COVID-19 clinical guide (5). Patient provided written informed consent prior the treatment with L/R was started. Additionally she received ceftriaxone, lidocainum, loratadinum, ambroxol and perindopril 10 mg, while zopiclon was canceled. On the third day of antiviral therapy, the patient suddenly complained of dizziness, nausea, and general malaise. Patient was disorientated; her heart rate was slow. Brain injury was classified as moderate, the Glasgow Coma Scale (GCS) was 12 points. The ECG showed sinus arrest with junctional escape rhythm 36 bpm (Fig. 1). The high sensitivity troponin, serum electrolytes, glomerular filtration rate, PH, PCO2, PO2, SaO2 were normal (Table 1).

Bedside 2-dimensional transthoracic echocardiogram demonstrated left ventricular hypertrophy, a preserved left ventricular ejection fraction of 60% by Simpson rule, without any regional wall motion abnormalities and estimated pulmonary artery systolic pressure was 45 mm Hg.

Figure 1. sinus arrest, junctional escape rhythm 36 bpm; RR =1640 msec, QTc (Framingham) = 507 msec
Table 1. Laboratory investigations

<table>
<thead>
<tr>
<th>Tests</th>
<th>Time of admission</th>
<th>Time of developing bradyarrhythmia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin, g/l</td>
<td>125</td>
<td>128</td>
</tr>
<tr>
<td>Serum creatinine, mmol/l</td>
<td>73.2</td>
<td>101.1</td>
</tr>
<tr>
<td>Glomerular filtration rate (Cockroft formula), ml/min/1.73 m²</td>
<td>63</td>
<td>46</td>
</tr>
<tr>
<td>Glucose, mmol/l</td>
<td>4.0</td>
<td>5.8</td>
</tr>
<tr>
<td>Serum potassium, mmol/l</td>
<td>4.8</td>
<td>4.0</td>
</tr>
<tr>
<td>High-sensitivity C-reactive protein, mg/l</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>High-sensitivity troponin I, ng/ml</td>
<td>-</td>
<td>&lt;0.010</td>
</tr>
<tr>
<td>Procalcitonin, ng/ml</td>
<td>-</td>
<td>0</td>
</tr>
<tr>
<td>PH</td>
<td>-</td>
<td>7.378</td>
</tr>
<tr>
<td>PCO₂, mmHg</td>
<td>-</td>
<td>35.1</td>
</tr>
<tr>
<td>PO₂, mmHg</td>
<td>-</td>
<td>35.0</td>
</tr>
<tr>
<td>SaO₂, %</td>
<td>95%</td>
<td>94%</td>
</tr>
</tbody>
</table>

Atropine sulphate and dopamine 5-6 mkg/kg/min iv were administered, but no effect on heart rate had been seen. Antiviral therapy was stopped, the patient received insertion of a temporary pacemaker, and a normal sinus rhythm was restored in 72 hours. She was discharged home in stable condition 14 days later. Her ECG after one month demonstrated normal sinus rhythm (Fig. 2).

Figure 2. sinus rhythm after 1 month of discharge from hospital
Discussion
Our patient was admitted to the hospital and started the L/R treatment because her SARS-CoV-2 RNA test was positive, her condition was evaluated as moderate disease severity and she had risk factors such as advanced age, hypertension and chronic obstructive pulmonary disease those are predictors of poor clinical outcomes. On a 3rd day after L/R 400mg/100 mg twice a day was started, patient become disorientated, her ECG showed sinus arrest with junctional rhythm 36 per min.
COVID-19 patients are likely to be at risk of arrhythmia due to underlying comorbidities, the myocardial injury, polypharmacy and toxicities of the potential medications used for COVID-19 treatment (6, 7). In the study from Wuhan, China, malignant arrhythmias were reported to be present in 16.7% of COVID-19 hospitalized patients and 44.4% of intensive care patients with COVID-19 (8).

Myocardial injury in COVID-19 is associated with impairment of cardiac function, inflammation, and an increased high sensitivity troponin. The underlying mechanisms of these abnormalities in the severe stage of COVID-19 may be resulted from inflammatory damage incurred by the virus, hypoxia, metabolic derangements, acidosis, intravascular volume imbalances, neurohormonal, and catecholaminergic stress (9). In our patient markers of myocardial injury such as left ventricular ejection fraction and high sensitive troponin were not pathological.

Our patient had severe bradycardia of 36 bpm occurred after three days of L/R treatment. Patient was disorientated that was evaluated as GCS 12 points. However, the patient did not have severe hypoxia as a room air oxygen saturation SaO2 was 94%, PCO2 35.1 mmHg, PO2 35.0 mmHg. The brain injury (disorientation) may be due to the toxic effect of L/R also.
L/R is the HIV protease inhibitor class of antiretroviral drugs cause dose-dependent block of human ether-a-go-go-related gene (HERG) potassium channels and predispose individuals to QT prolongation and torsade de pointes (10), especially in the setting of various co-
medications that are metabolized by CYP3A4. Some cardiovascular drugs such as atorvastatin, clopidogrel, rivaroxaban are major substrates of CYP3A4 (11). In our case, L/R was co-administered with ceftriaxone/lidocaine, loratadine, ambroxol, and perindopril. We do not found major interactions between these drugs when checked their co-administration in drug interaction checker. Our patient has other risk factors for QT prolongation such as female sex, hypertension, and advanced age (12). Her QTc was 507 msec that is prolonged. A prolonged QTc interval is the most famous surrogate marker of cardiotoxicity that can increase malignant arrhythmias (13).

Concurrent atazanavir and L/R administration was associated with PR and QRS interval changes in small study population (14). Bradycardia-tachycardia syndrome, first and second degree atrioventricular blocks induced by lopinavir-ritonavir have been documented in patients with acquired immunodeficiency syndrome (15-17). Our report also documented that L/R have potential to alter sinus node.
In study from China in hospitalized adult patients with severe COVID-19 no benefit was observed with L/R treatment beyond standard care and L/R treatment was stopped early in 13.8% patients because they had adverse events (18).
Experts recommended, if it was decided the patient has an indication for the use of drugs for the treatment of COVID 19, a clear administration protocols should be in every hospital and clinic using these drugs (19). Baseline checklist that is followed includes: baseline evaluation of serum electrolytes, drug-drug interaction, interruption of other nonessential drugs that can also prolong the QT, PQ, intervals and ECG parameters PQ, QRS, QTc should be measured (20, 21).
Conclusion
Bradyarrhythmia in form of sinus arrest can develop during treatment with lopinavir/ritonavir. The temporal nature of the observed changes and the ECG findings suggest the use of L/R contributed to the changes. This case highlights it is necessary to investigate balance between efficacy and safety of lopinavir/ritonavir for COVID-19 therapy. Off –label prescribing lopinavir/ritonavir outside of a clinical trial setting should be avoided until the data have proven that treatment benefit over placebo.

**Peer-review:** External and internal

**Conflict of interest:** None to declare

**Authorship:** Zh. Sh. T., B. Zh. M.S.K., B. K. Kh., Zh. E. Zh. equally contributed to preparation of manuscript and fulfilled authorship criteria

**Acknowledgments and funding:** None to declare

### References